1. Home
  2. APLM vs COSM Comparison

APLM vs COSM Comparison

Compare APLM & COSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • COSM
  • Stock Information
  • Founded
  • APLM 2016
  • COSM 2009
  • Country
  • APLM United States
  • COSM Greece
  • Employees
  • APLM N/A
  • COSM N/A
  • Industry
  • APLM Blank Checks
  • COSM Other Pharmaceuticals
  • Sector
  • APLM Finance
  • COSM Health Care
  • Exchange
  • APLM Nasdaq
  • COSM Nasdaq
  • Market Cap
  • APLM 7.7M
  • COSM 8.2M
  • IPO Year
  • APLM N/A
  • COSM 2013
  • Fundamental
  • Price
  • APLM $6.56
  • COSM $0.42
  • Analyst Decision
  • APLM Strong Buy
  • COSM
  • Analyst Count
  • APLM 1
  • COSM 0
  • Target Price
  • APLM $200.00
  • COSM N/A
  • AVG Volume (30 Days)
  • APLM 57.9K
  • COSM 353.1K
  • Earning Date
  • APLM 04-03-2025
  • COSM 04-16-2025
  • Dividend Yield
  • APLM N/A
  • COSM N/A
  • EPS Growth
  • APLM N/A
  • COSM N/A
  • EPS
  • APLM N/A
  • COSM N/A
  • Revenue
  • APLM $198,000.00
  • COSM $54,426,402.00
  • Revenue This Year
  • APLM $415.15
  • COSM $28.14
  • Revenue Next Year
  • APLM N/A
  • COSM N/A
  • P/E Ratio
  • APLM N/A
  • COSM N/A
  • Revenue Growth
  • APLM N/A
  • COSM 1.97
  • 52 Week Low
  • APLM $4.71
  • COSM $0.28
  • 52 Week High
  • APLM $49.00
  • COSM $1.58
  • Technical
  • Relative Strength Index (RSI)
  • APLM 50.05
  • COSM 52.78
  • Support Level
  • APLM $5.41
  • COSM $0.28
  • Resistance Level
  • APLM $6.19
  • COSM $0.45
  • Average True Range (ATR)
  • APLM 0.76
  • COSM 0.05
  • MACD
  • APLM 0.10
  • COSM 0.01
  • Stochastic Oscillator
  • APLM 86.05
  • COSM 83.43

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About COSM Cosmos Health Inc.

Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.

Share on Social Networks: